0001437749-18-014303.txt : 20180802 0001437749-18-014303.hdr.sgml : 20180802 20180802160017 ACCESSION NUMBER: 0001437749-18-014303 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180714 ITEM INFORMATION: Other Events FILED AS OF DATE: 20180802 DATE AS OF CHANGE: 20180802 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nuvectra Corp CENTRAL INDEX KEY: 0001648893 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 300513847 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37525 FILM NUMBER: 18988161 BUSINESS ADDRESS: STREET 1: 5830 GRANITE PKWY STREET 2: SUITE 1100 CITY: PLANO STATE: TX ZIP: 75024 BUSINESS PHONE: 972-668-4107 MAIL ADDRESS: STREET 1: 5830 GRANITE PKWY STREET 2: SUITE 1100 CITY: PLANO STATE: TX ZIP: 75024 FORMER COMPANY: FORMER CONFORMED NAME: QIG GROUP, LLC DATE OF NAME CHANGE: 20150722 8-K 1 nvtr20180801_8k.htm FORM 8-K nvtr20180801_8k.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 14, 2018

 

 

 

Nuvectra Corporation

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

001-37525

30-0513847

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification Number)

  

5830 Granite Parkway, Suite 1100,

Plano, Texas 75024

(Address of principal executive offices, including zip code)

 

(214) 474-3103

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☒

 

 

 

 
 

 

Item 8.01

Other Events

 

Departure Prior Chief Technology Officer and Hiring of New Chief Technology Officer

 

On July 14, 2018, Dr. Norbert Kaula notified Nuvectra Corporation (the “Company”) that he was resigning from his position of Chief Technology Officer, effective as of August 17, 2018. Dr. Kaula has agreed to assist with his exit from the Company to ensure a smooth transition of all ongoing key projects and matters. Dr. Kaula has indicated that his decision to resign from his position is not due to any disagreements with the Company on any matter relating to its operations, policies or practices and he is leaving to pursue other opportunities.

 

The Company announced on August 2, 2018, that it appointed Mr. Ben Tranchina as Chief Technology Officer, effective August 24, 2018. Mr. Tranchina will be primarily responsible for the Company’s Research & Development and its Engineering Departments, which includes management and oversight of all product development and testing, research into future products and indications, continuing engineering and expansion of the Company’s IP portfolio. Mr. Tranchina has more than 25 years of experience in technology business leadership for early-stage to multi-national commercial companies and more than 30 issued or pending U.S. patents relevant to neuromodulation. Prior to joining Nuvectra, he was the Chief Technology Officer of Neurotechnology Innovations Translator (NIT), LLC, a privately held company which develops and commercializes neurotechnology solutions. During his tenure at NIT, he also served as Chief Executive Officer for its affiliate, Veressa Medical, Inc. Previously, he was President and CEO of Ardent Biomedical, LLC, a specialty strategic and technical advisory practice dedicated to enabling commercialization of innovative therapeutic and diagnostic medical device solutions. Mr. Tranchina has also served in various leadership roles at companies such as InCube Labs and Advanced Neuromodulation Systems, Inc., as well as Vice President of Product Development, responsible for the neuromodulation portfolio at St. Jude Medical. During his time at St. Jude Medical, nine first-to-market products were launched and he was awarded St. Jude Medical’s Neuromodulation Inventor of the Year for 2007. Mr. Tranchina holds Bachelor's and Master's degrees in Electrical Engineering from the University of Texas at Dallas, specializing in Microelectronic Circuits and Systems.

 

 
 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

August 2, 2018 

NUVECTRA CORPORATION 

 

 

 

 

 

By: /s/ Walter Z. Berger                                        

 

Name: Walter Z. Berger                                        

 

Title: COO & CFO